Evidence map›Paper›PMID 38868333›Full record

ArticleiMeta2023

OmicStudio: A composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication.

Fengye Lyu, Feiran Han, Changli Ge, Weikang Mao, Li Chen, Huipeng Hu, Guoguo Chen, Qiulei Lang, Chao Fang

Abstract read
In one paragraph

Article in iMeta, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers.

0numbers the graph read from it
0cells of the map it votes in
190citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

190 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. CRISPR-MediatedCells · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

130 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fengye LyuOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Feiran HanOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Changli GeOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Weikang MaoOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Li ChenOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Huipeng HuOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Guoguo ChenOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Qiulei LangOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.
Chao FangOperation Department LC-Bio Technology Co., Ltd. Hangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OmicStudio focuses on speed, quality together with flexibility. Generally, OmicStudio can not only meet the users' demand of ordinary bioinformatics data analysis, statistics, and visualization, but also provides them freedom of data mining beyond developer's framework. Additionally, unlimited to developer's aesthetics, users can get more elegant graphs through customizing. Available online https://www.omicstudio.cn.

Identifiers

PMID38868333
PMCPMC10989813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.